絞り込み

16638

広告

Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.

著者 Landa G , Amde W , Doshi V , Ali A , McGevna L , Gentile RC , Muldoon TO , Walsh JB , Rosen RB
Ophthalmologica.2009 ; 223(6):370-5.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Retina Center, Department of Ophthalmology, New York Eye and Ear Infirmary, New York, N.Y., USA.

スターを付ける スターを付ける     (449view , 0users)

Full Text Sources

Medical

To compare the safety and efficacy of 2 anti-vascular-endothelial-growth-factor agents - bevacizumab (Avastin) versus ranibizumab (Lucentis) - in the treatment of patients with neovascular age-related macular degeneration (AMD).
PMID: 19590252 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード